178445-80-2

Basic information

• Product Name: (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE
• Synonyms: (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE;(E)-3-(3,4-Dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one;(E)-3,4-Dimethoxy-3^-hydroxychalcone;(2E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
• CAS NO: 178445-80-2
• Molecular Formula: C₁₇H₁₆O₄
• Molecular Weight: 284.31
• Mol File: 178445-80-2.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 488.2°Cat760mmHg
• Flash Point: 180.7°C
• Appearance: /
• Density: 1.203g/cm³
• Vapor Pressure: 3.74E-10mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE(178445-80-2)
• EPA Substance Registry System: (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE(178445-80-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 178445-80-2(Hazardous Substances Data)

Usage

General Description

The chemical compound "(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)-1-propenone" is a ketoenol compound with the molecular formula C17H16O4. It has a trans configuration, indicated by the "(E)" prefix, and consists of a phenyl group with two methoxy substituents and a hydroxyphenyl group attached to a propenone moiety. (E)-3-(3,4-DIMETHOXYPHENYL)-1-(3-HYDROXYPHENYL)-1-PROPENONE is commonly used in organic synthesis and pharmaceutical research due to its potential biological activities, including anti-inflammatory and antioxidant properties. It has also been studied for its potential role in cancer treatment and as a chemical intermediate in the synthesis of other compounds. Additionally, it may have applications in the flavor and fragrance industries.

InChI:InChI=1/C17H16O4/c1-20-16-9-7-12(10-17(16)21-2)6-8-15(19)13-4-3-5-14(18)11-13/h3-11,18H,1-2H3/b8-6+

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 178445-82-4 (2E)-3-(1,3-benzodioxol-5-yl)-1-(3-hydroxyphenyl)prop-2-en-1-one 
• 1373829-44-7 2-(3-((R)-1-(((S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid 
• 1323151-35-4 tert-butyl 2-(3-(3-(3,4-dimethoxyphenyl)-1-hydroxypropyl)phenoxy)acetate 
• 178445-89-1 (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol 
• 1374119-33-1 (R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)-propan-1-ol 
• 914805-33-7 (R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate 
• 195202-03-0 (S)-((R)-1-(3-(2-tert-butoxy-2-oxoethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propyl) piperidine-2-carboxylate 
• 195202-02-9 (S)-1-(9H-fluoren-9-yl)methyl 2-((R)-1-(3-(2-tert-butoxy-2-oxo-ethoxy) phenyl)-3-(3,4-dimethoxyphenyl)propyl) piperidine-1,2-dicarboxylate 
• 1392284-65-9 C₄₄H₅₇N₃O₁₀ 

Relevant articles and documents

RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have grea

Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35

FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.

Polyhydroxy chalcone compound and application thereof

The invention provides a polyhydroxy chalcone compound and application thereof. The compound has a good inhibiting effect on aggregation of Abeta protein, and can eliminate or reduce toxicity caused by Abeta protein aggregation effectively in a cell exper